%0 Journal Article
%A Kaulen, Leon
%A Karschnia, Philipp
%A Doubrovinskaia, Sofia
%A Abramson, Jeremy S
%A Soumerai, Jacob D
%A Martinez-Lage, Maria
%A Haydu, J Erika
%A Shankar, Ganesh M
%A Patel, Chirayu
%A Choi, Bryan D
%A Barnes, Jeffrey A
%A El-Jawahri, Areej
%A Hochberg, Ephraim P
%A Johnson, P Connor
%A Wick, Wolfgang
%A Maus, Marcela V
%A Chen, Yi-Bin
%A Frigault, Matthew J
%A Dietrich, Jorg
%T Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma.
%J Journal of hematology & oncology
%V 19
%N 1
%@ 1756-8722
%C London
%I Biomed Central
%M DKFZ-2026-00114
%P 2
%D 2026
%Z #DKTKZFB26#
%X CD19-directed chimeric antigen receptor T-cell therapy (CD19-CAR) has yielded encouraging efficacy in CNS lymphomas (CNSL), but most patients ultimately experience progressive disease (PD). Risk factors, progression patterns as well as optimal salvage therapies remain unclear.Clinical and radiological characteristics of CD19-CAR failure were therefore retrospectively defined in CNSL treated at Massachusetts General Hospital from 2018 to 2024. PD patterns were defined as local or distant. CNS-progression-free survival from CD19-CAR infusion (CNS-PFS1) and first subsequent progression (CNS-PFS2) were analyzed.CD19-CAR achieved a 60
%K Humans
%K Male
%K Central Nervous System Neoplasms: therapy
%K Central Nervous System Neoplasms: immunology
%K Central Nervous System Neoplasms: pathology
%K Central Nervous System Neoplasms: mortality
%K Female
%K Antigens, CD19: immunology
%K Middle Aged
%K Aged
%K Risk Factors
%K Retrospective Studies
%K Adult
%K Immunotherapy, Adoptive: methods
%K Immunotherapy, Adoptive: adverse effects
%K Lymphoma: therapy
%K Lymphoma: immunology
%K Receptors, Chimeric Antigen: immunology
%K Aged, 80 and over
%K Treatment Failure
%K Chimeric antigen receptor t-cell therapy (Other)
%K Diffuse large b-cell lymphoma (Other)
%K Immunotherapy (Other)
%K Magnetic resonance imaging (Other)
%K Primary CNS lymphomas (Other)
%K Progression patterns (Other)
%K Salvage therapy (Other)
%K Antigens, CD19 (NLM Chemicals)
%K Receptors, Chimeric Antigen (NLM Chemicals)
%K CD19 molecule, human (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41530773
%R 10.1186/s13045-025-01761-8
%U https://inrepo02.dkfz.de/record/307653